Skip to content
Tenfell
Awarded contract
Published 15 Nov 2022

VIR-7831 Supply Agreement for Pandemic Purposes

Department of Health and Social Care · London

Key facts

Contract value
£5
Awarded
10 Aug 2021
Contract starts
10 Aug 2021
Contract ends
31 Mar 2022
Procedure
Negotiated procedure without prior publication (above threshold)
Buyer type
Central government

Awarded to

SupplierValue
GlaxoSmithKline£1

Description

The evolution of the UK's pandemic response has highlighted the critical importance and economic value of a multi-layered and comprehensive approach to COVID-19. The need for antibodies and other therapeutics has always been under consideration, the mutation of the virus and the risk this poses on antibody and vaccine efficacy has only recently been properly identified and still requires further academic studies. These unforeseen circumstances mean there is now a critical, urgent need to procure and deploy a new class of mAbs, that can neutralise any COVID-19 variant. These neutralising mAbs provide protection to a cohort of the population who, for medical reasons, cannot mount an appropriate immune response to vaccination or, for whatever reason, do not get vaccinated and are also at higher risk of hospitalisation or death. This agreement is for the procurement of 100,008 units of Sotrovimab (VIR-7831).

Categories (CPV)

Similar open tenders

About Department of Health and Social Care

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.